#Canada #Toronto #Imaging Technology #Wound Care #MolecuLight

MolecuLight Showcases Innovations at SAWC Fall 2025

MolecuLight Inc., a pioneer in point-of-care fluorescence imaging for wound management, is thrilled to announce its continued contributions to the field of wound care at the Symposium on Advanced Wound Care (SAWC) Fall 2025. The event, held from September 3-6 in Las Vegas, NV, features MolecuLight exhibiting its cutting-edge MolecuLightDX®+ device at Booth #327, bringing attendees firsthand demonstrations of its advanced imaging technology.

As a highlight of the conference, MolecuLight presents ten scientific posters that underscore the vast clinical applications enabled by its multimodal imaging platform. These posters encompass vital topics that could significantly influence wound management practices:

• - Patient Engagement and Education: Exploring strategies to enhance communication and shared decision-making between care teams and patients through effective imaging techniques.
• - Intraoperative and Preoperative Use: Supporting surgical teams with real-time insights on wound conditions to optimize surgical outcomes.
• - Wound Hygiene and Debridement: Identifying bacterial hotspots to refine debridement approaches, improving patient care quality.
• - Thermal Imaging in Wound Care: Investigating the impact of temperature mapping as a tool for objective wound assessments, deepening clinicians' understanding of wound characteristics.

Notably, the MolecuLightDX®+ platform is set to expand its imaging capabilities to include oxygenation assessment, allowing healthcare providers to gauge oxygen levels, identify bacterial burdens, and accurately measure wound dimensions—all from a single, handheld device. This innovative integration aims to enhance clinician efficiency and streamline documentation processes. The company anticipates submitting this groundbreaking new feature for FDA approval by the fourth quarter of 2025.

The MolecuLightDX®+ device already integrates seamlessly with leading electronic health record (EHR) systems, including Epic. This enhancement promises to bolster clinical workflow efficiencies further, enabling healthcare professionals to focus more on patient outcomes rather than juggling multiple technologies. Additionally, MolecuLight is pursuing Medical Device Development Tool (MDDT) qualification with the FDA for its wound measurement function, which will affirm its accuracy and reliability for clinical assessments.

Anil Amlani, CEO of MolecuLight, emphasized the conference's importance in driving forward the future of wound care. He stated, "SAWC Fall is a leading forum for advancing wound care, and we're proud to contribute to the scientific dialogue through our ten posters that showcase the broad clinical value of MolecuLight's technology. Our upcoming oxygenation imaging will represent a leap forward, creating a comprehensive handheld solution to enhance clinician capabilities and ultimately improve patient outcomes."

Attendees at SAWC Fall 2025 are encouraged to visit MolecuLight at Booth #327 to experience live demonstrations of the MolecuLightDX®+, as the company aims to showcase how its technologies are revolutionizing wound assessment and documentation processes, while deeply integrating into everyday clinical workflows.

About MolecuLight

MolecuLight is a globally recognized medical imaging company, specializing in the design and distribution of advanced imaging solutions for wound care. With devices such as the MolecuLight iX® and DX®, which are FDA-cleared for real-time bacterial burden detection, the company emphasizes comprehensive wound management backed by substantial clinical evidence, including over 100 peer-reviewed studies.

About SAWC Fall

The Symposium on Advanced Wound Care is North America's premier multidisciplinary conference dedicated to wound management, uniting clinicians, researchers, and industry leaders to foster collaboration and education that leads to improved patient care worldwide.